Ken Griffin Evelo Biosciences, Inc. Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.44 - $48.2 $14,330 - $479,686	9,952 New	9,952 $16,000
Q2 2022 Aug 15, 2022	BUY	$1.46 - $3.55 $64,803 - $157,570	44,386 Added 70.41%	107,423 $226,000
Q1 2022 May 16, 2022	BUY	$2.66 - $6.63 $14,002 - $34,900	5,264 Added 9.11%	63,037 $214,000
Q4 2021 Feb 14, 2022	BUY	$6.07 - $12.0 $232,450 - $459,540	38,295 Added 196.61%	57,773 $350,000
Q2 2021 Aug 16, 2021	SELL	$9.43 - $16.6 $152,879 - $269,119	-16,212 Reduced 45.42%	19,478 $267,000
Q1 2021 May 17, 2021	BUY	$9.71 - $18.6 $126,463 - $242,246	13,024 Added 57.46%	35,690 $382,000
Q4 2020 Feb 16, 2021	BUY	$3.91 - $12.28 $88,624 - $278,338	22,666 New	22,666 $274,000
Q2 2020 Aug 14, 2020	SELL	$3.53 - $6.12 $36,094 - $62,577	-10,225 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$3.21 - $7.06 $32,822 - $72,188	10,225 New	10,225 $38,000

Ticker EVLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,994,000
Description
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hy...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.